SCHEMBL945862

SCHEMBL945862

CC(C)NS(=O)(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.61
ALDH1A1 P00352 4/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
NPSR1 Q6W5P4 2/20 0.57
MMP2 P08253 4/20 0.55
CA12 O43570 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
ADAMTS4 O75173 2/20 0.53
MMP13 P45452 3/20 0.52
MMP1 P03956 2/20 0.52
MMP9 P14780 2/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MMP8 P22894 1/20 0.52
SLC1A3 P43003 2/20 0.50
SLC1A2 P43004 2/20 0.50
SLC1A1 P43005 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11512348 0.98 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6613031 0.88 ADAMTS4 (0.70) SMN1; SMN2ALDH1A1CYP2C9CYP2C19NPSR1
Benzene SCHEMBL29019330 0.85 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL4714253 0.84 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6006659 0.84 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL16000107 0.83 LARS1 (0.55) MMP2ADAMTS4MMP13MMP1MMP9
SCHEMBL16000119 0.83 MMP9 (0.68) SMN1; SMN2ALDH1A1NPSR1MMP2ADAMTS4
SCHEMBL19808134 0.83 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL14701615 0.83 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL7791079 0.83 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4456999-A1 A SYSTEM FOR PURIFICATION OF ACRYLAMIDO TERTIARYBUTYL SULFONIC ACID AND PROCESS THEREOF Vinati Organics Limited (IN) 2024-11-06 EP claimed
US-20240343685-A1 SYSTEM FOR PURIFICATION OF ACRYLAMIDO TERTIARY BUTYL SULFONIC ACID AND PROCESS THEREOF VINATI ORGANICS LIMITED (IN) 2024-10-17 US claimed
CN-117903526-A Anti-sticky scratch-resistant PP resin composition, and preparation method and application thereof 江苏金发科技新材料有限公司 2024-04-19 CN claimed
CN-117903015-A Process for the preparation of N-fluoro-N-alkylsulfonamides 中国科学院上海有机化学研究所 2024-04-19 CN claimed
WO-2023118976-A1 A SULFONATING MIXTURE FOR SYNTHESIS OF ACRYLAMIDO TERTIARY BUTYL SULFONIC ACID AND PREPARATION PROCESS THEROF VINATI ORGANICS LIMITED (IN) 2023-06-29 WO claimed
CN-114249980-B Glass fiber reinforced polyamide material for plastic high-pressure water gun and preparation method thereof 上海聚威新材料股份有限公司 2023-03-21 CN claimed
CN-114249979-B Polyamide composition with NTC effect and preparation method thereof 金发科技股份有限公司 2022-08-30 CN claimed
CN-114728009-A Preventing or treating diseases and disorders associated with tissue damage 李晓祥 2022-07-08 CN claimed
CN-114249980-A Glass fiber reinforced polyamide material for plastic high-pressure water gun and preparation method thereof 上海聚威新材料股份有限公司 2022-03-29 CN claimed
CN-114249979-A Polyamide composition with NTC effect and preparation method thereof 金发科技股份有限公司 2022-03-29 CN claimed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO claimed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP claimed
CN-1788001-A 2, 4-bis (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2006-06-14 CN claimed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO claimed
EP-1497261-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-01-19 EP claimed
US-6828375-B2 Containing a thermoplastic elastomer grafted with maleic anhydride, carbon black powder, sulfonamide based material, and alkanedioic acid HYUNDAI MOTOR COMPANY (KR) 2004-12-07 US claimed
EP-1165866-B1 ABRASIVE FILAMENTS OF PLASTICIZED POLYAMIDES DU PONT (US) 2004-01-28 EP claimed
WO-2003091204-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-11-06 WO claimed
US-20020128373-A1 Electroconductive polyamide resin composition and molded product for motor component prepared therefrom HYUNDAI MOTOR COMPANY (KR) 2002-09-12 US claimed
US-5437690-A Using an n-alkyl aromatic sulfonamide as dye promoter in dyeing aromatic polyamides, polybenzimidazoles, polyimides SPRINGS INDUSTRIES, INC. (US) 1995-08-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343685-A1 SYSTEM FOR PURIFICATION OF ACRYLAMIDO TERTIARY BUTYL SULFONIC ACID AND PROCESS THEREOF ATIC, MRPS18B, AGPS SMN1; SMN2 3908/4885ALDH1A1 2263/4885CYP1A2 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.